Scholarlink

<p>Antibody-targeted radioimmunotherapy holds significant potential for solid tumor treatment. However, intact antibodies (IgG) and fragments (F(ab’)<sub>2</sub>) may exhibit distinct pharmacokinetic and radiation delivery properties due to differences in molecular size and Fc functionality. TROP2 is highly overexpressed in most malignant tumors but minimally expressed in normal tissues. Therefore, the anti-TROP2 antibody was selected as the targeting agent in this study. We prepared the F(ab’)<sub>2</sub> antibody fragments of anti-TROP2 antibody and systematically compared the in vitro and in vivo behaviors of [<sup>177</sup>Lu]Lu-DOTA-anti-TROP2 antibody and [<sup>177</sup>Lu]Lu-DOTA-anti-TROP2-F(ab’)<sub>2</sub> antibody fragments to optimize radioligand therapy strategies. Cell binding assays were conducted to evaluate their TROP2 antigen binding affinity. In vivo distributions in tumors and normal organs were investigated through Micro-SPECT/CT imaging and biodistribution studies using tumor-bearing mice. The results demonstrated that, compared to the anti-TROP2 antibody, the anti-TROP2-F(ab’)<sub>2</sub> antibody fragments exhibited superior blood clearance kinetics as well as lower accumulation in liver and spleen. This could reduce the radiation side effects of [<sup>177</sup>Lu]Lu-DOTA-anti-TROP2-F(ab’)<sub>2</sub> antibody fragments on bone marrow or other full-antibody target normal organs. However, cutting Fc from the full anti-TROP2 antibody increased renal accumulation and exhibited shedding phenomena following tumor targeting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

177Lu-labeled anti-TROP2 antibody and its F(ab’)2 fragment for radioimmunotherapy of lung cancer: preparation and biological evaluation

  • 期刊论文

  • 发表日期：

    2026年5月12日

查看全文
  • Jiayan Yu,
  • Tao Wang,
  • Jiajia Li,
  • Zhiyou He,
  • Jing Wang,
  • Peng Zhao,
  • Yue Chen,
  • Xia Yang

摘要

Antibody-targeted radioimmunotherapy holds significant potential for solid tumor treatment. However, intact antibodies (IgG) and fragments (F(ab’)2) may exhibit distinct pharmacokinetic and radiation delivery properties due to differences in molecular size and Fc functionality. TROP2 is highly overexpressed in most malignant tumors but minimally expressed in normal tissues. Therefore, the anti-TROP2 antibody was selected as the targeting agent in this study. We prepared the F(ab’)2 antibody fragments of anti-TROP2 antibody and systematically compared the in vitro and in vivo behaviors of [177Lu]Lu-DOTA-anti-TROP2 antibody and [177Lu]Lu-DOTA-anti-TROP2-F(ab’)2 antibody fragments to optimize radioligand therapy strategies. Cell binding assays were conducted to evaluate their TROP2 antigen binding affinity. In vivo distributions in tumors and normal organs were investigated through Micro-SPECT/CT imaging and biodistribution studies using tumor-bearing mice. The results demonstrated that, compared to the anti-TROP2 antibody, the anti-TROP2-F(ab’)2 antibody fragments exhibited superior blood clearance kinetics as well as lower accumulation in liver and spleen. This could reduce the radiation side effects of [177Lu]Lu-DOTA-anti-TROP2-F(ab’)2 antibody fragments on bone marrow or other full-antibody target normal organs. However, cutting Fc from the full anti-TROP2 antibody increased renal accumulation and exhibited shedding phenomena following tumor targeting.